Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sickle-AID: Nonmyeloablative HSCT in Pediatric Sickle Cell Disease
NCT03214354Phase 2Recruiting
- Sponsor
- University of Calgary
- Start
- Jul 2017
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, nab-sirolimus in sickle cell disease (SCD), sponsored by University of Calgary. Started Jul 2017; status: recruiting.
02
Drugs
alemtuzumabnab-sirolimus
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03214354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214354.